IRVINE, CA--(Marketwired - Feb 5, 2014) - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received CE ...
Company Receives CE Mark Approval for 29 mm Transfemoral System First Human Experience With Next-Generation Valve Platforms to Be Presented PARIS-- Edwards Lifesciences Corporation, the global leader ...
PARIS--(Marketwired - May 21, 2013) - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that one-year data from ...
* Sapien XT, Sapien show similar death, stroke rates at 1 yr * Fewer complications seen with newer XT model after 30 days By Bill Berkrot SAN FRANCISCO, March 10 (Reuters) - A smaller, redesigned ...
Heart transcatheter The FDA has approved an expanded indication for the Sapien XT and Sapien 3 transcatheter heart valves (Edwards Lifesciences) for patients with aortic valve stenosis who are at ...
The new Sapien XT aortic valve showed a non-significantly lower rate of death and strokes at 30 days than the original model, and both valves demonstrated notably better short-term outcomes than seen ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Use of the Sapien XT transcatheter valve in patients with high-risk aortic stenosis undergoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results